Short answer
Abbott Laboratories (ABT) filed its Q2 2026 10-Q quarterly report on Jul 28, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $12.6B (up 13.0% year over year) with net income of $928M.
Q2 2026 key financials · XBRL
- Revenue
- $12.6B
- +13.0% YoY · +12.8% QoQ
- Net income
- $928M
- −47.8% YoY · −13.8% QoQ
- Operating margin
- 13.4%
- EPS (diluted)
- $0.53
- −47.5% YoY · −13.1% QoQ
Source: XBRL data from the Abbott Laboratories (ABT) Q2 2026 10-Q on SEC EDGAR. USD.
Abbott Laboratories Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $12.593B, up 13.0% YoY from $11.142B
- Gross margin 52.5% vs 52.7% YoY, pressured by Exact Sciences amortization and higher costs
- Best segment Diagnostic Products $3.092B, up 42.3%; worst Nutritional Products $2.144B, down 3.1%
- Cash $5.1B vs $8.5B at December 31; operating cash flow $3.8B, up $339M
- Exact Sciences acquisition $20.6B; $20.0B funded through long-term debt and $1.0B share repurchases in six months
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Abbott Laboratories quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.